Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
Open Access
- 1 October 2003
- journal article
- review article
- Published by The Endocrine Society in Endocrine Reviews
- Vol. 24  (5) , 633-667
- https://doi.org/10.1210/er.2002-0015
Abstract
Polycystic ovary syndrome (PCOS) is a medical condition that has brought multiple specialists together. Gynecologists, endocrinologists, cardiologists, pediatricians, and dermatologists are all concerned with PCOS patients and share research data and design clinical trials to learn more about the syndrome. Insulin resistance is a common feature of PCOS and is more marked in obese women, suggesting that PCOS and obesity have a synergistic effect on the magnitude of the insulin disorder. Hyperinsulinemia associated with insulin resistance has been causally linked to all features of the syndrome, such as hyperandrogenism, reproductive disorders, acne, hirsutism, and metabolic disturbances. Women with PCOS should be evaluated for cardiovascular risk factors, such as lipid profile and blood pressure. Modification of diet and lifestyle should be suggested to those who are obese. Several insulin-lowering agents have been tested in the management of PCOS. In particular, metformin is the only drug currently in widespread clinical use for treatment of PCOS. In a high percentage of patients, treatment with metformin is followed by regularization of menstrual cycle, reduction in hyperandrogenism and in cardiovascular risk factors, and improvement in response to therapies for induction of ovulation.Keywords
This publication has 304 references indexed in Scilit:
- PioglitazoneDrugs, 2000
- Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary SyndromeNew England Journal of Medicine, 1999
- Pharmacokinetic-Pharmacodynamic Relationships of AcarboseClinical Pharmacokinetics, 1996
- Coronary Heart Disease Risk Factors in Women With Polycystic Ovary SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Risk Factors for Coronary Artery Disease in Healthy Persons with Hyperinsulinemia and Normal Glucose ToleranceNew England Journal of Medicine, 1989
- Pituitary-Ovarian Responses to Nafarelin Testing in the Polycystic Ovary SyndromeNew England Journal of Medicine, 1989
- AcarboseDrugs, 1988
- Insulin Resistance in Essential HypertensionNew England Journal of Medicine, 1987
- A Chronobiologic Abnormality in Luteinizing Hormone Secretion in Teenage Girls with the Polycystic-Ovary SyndromeNew England Journal of Medicine, 1983
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982